Physician profile
Jasmine Johnson
NPI 1790261782
$652.46
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $434 · 2022: $219.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $148.10 | 2021 | |
| Grt US Holding, INC. | $84.56 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $78.59 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.74 | 2021-2022 | |
| Ibsa Pharma INC. | $57.72 | 2021-2022 | |
| Eisai INC. | $57.36 | 2021-2022 | |
| Si-Bone, INC. | $50.86 | 2022 | |
| Lilly USA, LLC | $42.53 | 2022 | |
| Amgen INC. | $20.40 | 2021 | |
| Hologic Sales and Service, LLC | $17.31 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.80 | 2022 | |
| Collegium Pharmaceutical, INC. | $14.49 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.